BC
AMPH icon

Broadfin Capital’s Amphastar Pharmaceuticals AMPH Stock Holding History

Broadfin Capital’s Portfolio AMPH Stock Details AMPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-1,026,979
Closed -$14.6M – 72
2015
Q4 		$14.6M Sell
1,026,979
-250,000
-20% -$3.3M 0.9% 29
2015
Q3 		$14.9M Sell
1,276,979
-140,977
-10% -$2.11M 0.83% 30
2015
Q2 		$24.9M Sell
1,417,956
-709,898
-33% -$11.1M 1.34% 17
2015
Q1 		$31.8M Hold
2,127,854
– – 2.48% 9
2014
Q4 		$24.7M Buy
2,127,854
+150,000
+8% +$1.63M 2.15% 13
2014
Q3 		$23M Buy
+1,977,854
New +$20.6M 2.42% 12

Other funds holding AMPH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TA
Teachers Advisors New York $81.7B AUM 13.62% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Broadfin Capital's AMPH Position: Q1 2016 in Review

Broadfin Capital sold out of Amphastar Pharmaceuticals (AMPH) in Q1 2016, closing a stake of 1,026,979 shares — an estimated $14.6M sold.

Broadfin Capital first reported a position in AMPH in Q3 2014 and held it in 6 quarters. The position peaked at $31.8M in Q1 2015. 95 funds tracked by Wall St. Rank hold AMPH as of Q1 2016.

  • Broadfin Capital reported no remaining Amphastar Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
  • Broadfin Capital sold 1,026,979 Amphastar Pharmaceuticals shares in Q1 2016, an estimated $14.6M.
  • Broadfin Capital first reported a position in Amphastar Pharmaceuticals in Q3 2014 and held it in 6 quarters.
  • Broadfin Capital's Amphastar Pharmaceuticals position peaked at $31.8M in Q1 2015.
  • 95 funds tracked by Wall St. Rank held Amphastar Pharmaceuticals as of Q1 2016.

Based on Broadfin Capital's 13F filing for Q1 2016, filed 16 May 2016.